Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study

Matt D.T. Hitchings, Otavio T. Ranzani, Mario Sergio Scaramuzzini Torres, Silvano Barbosa de Oliveira, Maria Almiron, Rodrigo Said, Ryan Borg, Wade L. Schulz, Roberto Dias de Oliveira, Patricia Vieira da Silva, Daniel Barros de Castro, Vanderson de Souza Sampaio, Bernardino Cláudio de Albuquerque, Tatyana Costa Amorim Ramos, Shadia Hussami Hauache Fraxe, Cristiano Fernandes da Costa, Felipe Gomes Naveca, Andre M. Siqueira, Wildo Navegantes de Araújo, Jason R. Andrews, Derek A.T. Cummings, Albert I. Ko, Julio Croda
doi: https://doi.org/10.1101/2021.04.07.21255081
Matt D.T. Hitchings
1Department of Biology, University of Florida, Gainesville, FL, USA
2Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Otavio T. Ranzani
3Pulmonary Division, Heart Institute (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil
4Barcelona Institute for Global Health, ISGlobal, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mario Sergio Scaramuzzini Torres
5Municipal Health Secretary of Manaus, Brazil, AM, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Silvano Barbosa de Oliveira
6Pan American Health Organization, Brasília, DF, Brazil
7Universidade de Brasília, Brasília, DF, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Almiron
6Pan American Health Organization, Brasília, DF, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rodrigo Said
6Pan American Health Organization, Brasília, DF, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryan Borg
8Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wade L. Schulz
9Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT, USA
10Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roberto Dias de Oliveira
11State University of Mato Grosso do Sul - UEMS, Dourados, MS, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia Vieira da Silva
12Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Barros de Castro
13Fundação de Vigilância em Saúde do Estado do Amazonas, Manaus, AM, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vanderson de Souza Sampaio
13Fundação de Vigilância em Saúde do Estado do Amazonas, Manaus, AM, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernardino Cláudio de Albuquerque
13Fundação de Vigilância em Saúde do Estado do Amazonas, Manaus, AM, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatyana Costa Amorim Ramos
13Fundação de Vigilância em Saúde do Estado do Amazonas, Manaus, AM, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shadia Hussami Hauache Fraxe
5Municipal Health Secretary of Manaus, Brazil, AM, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristiano Fernandes da Costa
13Fundação de Vigilância em Saúde do Estado do Amazonas, Manaus, AM, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Felipe Gomes Naveca
14Fiocruz, Instituto Leônidas e Maria Deane, Manaus, AM, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andre M. Siqueira
15Instituto Nacional de Infectologia Carlos Chagas-Fiocruz, Rio de Janeiro, RJ, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wildo Navegantes de Araújo
6Pan American Health Organization, Brasília, DF, Brazil
7Universidade de Brasília, Brasília, DF, Brazil
16National Institute for Science and Technology for Health Technology Assessment, Porto Alegre, RS, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason R. Andrews
17Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Derek A.T. Cummings
1Department of Biology, University of Florida, Gainesville, FL, USA
2Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Albert I. Ko
8Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
18Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, BA, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julio Croda
8Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
12Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil
19Fiocruz Mato Grosso do Sul, Fundação Oswaldo Cruz, Campo Grande, MS, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: julio.croda@fiocruz.br
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, Gamma, emerged in the city of Manaus in late 2020 during a large resurgence of coronavirus disease (COVID-19), and has spread throughout Brazil. The effectiveness of vaccines in settings with widespread Gamma variant transmission has not been reported.

Methods We performed a matched test-negative case-control study to estimate the effectiveness of an inactivated vaccine, CoronaVac, in healthcare workers (HCWs) in Manaus, where the Gamma variant accounted for 86% of genotyped SARS-CoV-2 samples at the peak of its epidemic. We performed an early analysis of effectiveness following administration of at least one vaccine dose and an analysis of effectiveness of the two-dose schedule. The primary outcome was symptomatic SARS-CoV-2 infection.

Findings For the early at-least-one-dose and two-dose analyses the study population was, respectively, 53,176 and 53,153 HCWs residing in Manaus and aged 18 years or older, with complete information on age, residence, and vaccination status. Among 53,153 HCWs eligible for the two-dose analysis, 47,170 (89%) received at least one dose of CoronaVac and 2,656 individuals (5%) underwent RT-PCR testing from 19 January, 2021 to 13 April, 2021. Of 3,195 RT-PCR tests, 885 (28%) were positive. 393 and 418 case- control pairs were selected for the early and two-dose analyses, respectively, matched on calendar time, age, and neighbourhood. Among those who had received both vaccine doses before the RT-PCR sample collection date, the average time from second dose to sample collection date was 14 days (IQR 7-24). In the early analysis, vaccination with at least one dose was associated with a 0.50-fold reduction (adjusted vaccine effectiveness (VE), 49.6%, 95% CI 11.3 to 71.4) in the odds of symptomatic SARS-CoV-2 infection during the period 14 days or more after receiving the first dose. However, we estimated low effectiveness (adjusted VE 36.8%, 95% CI -54.9 to 74.2) of the two-dose schedule against symptomatic SARS-CoV-2 infection during the period 14 days or more after receiving the second dose. A finding that vaccinated individuals were much more likely to be infected than unvaccinated individuals in the period 0-13 days after first dose (aOR 2.11, 95% CI 1.36-3.27) suggests that unmeasured confounding led to downward bias in the vaccine effectiveness estimate.

Interpretation Evidence from this test-negative study of the effectiveness of CoronaVac was mixed, and likely affected by bias in this setting. Administration of at least one vaccine dose showed effectiveness against symptomatic SARS-CoV-2 infection in the setting of epidemic Gamma variant transmission. However, the low estimated effectiveness of the two-dose schedule underscores the need to maintain non-pharmaceutical interventions while vaccination campaigns with CoronaVac are being implemented.

Funding Fundação Oswaldo Cruz (Fiocruz); Municipal Health Secretary of Manaus

Evidence before this study We searched PubMed for articles published from inception of the pandemic until April 3, 2021, with no language restrictions, using the search terms “P.1” AND “vaccine” AND “SARS-CoV-2”. Additionally, we searched for “CoronaVac” AND “SARS-CoV-2”. Early studies have found plasma from convalescent COVID-19 patients and sera from vaccinated individuals have reduced neutralisation of the SARS-CoV-2 variant, Gamma or P.1, compared with strains isolated earlier in the pandemic. Pfizer BNT162b2 mRNA, Oxford-AstraZeneca ChAdOx1, and CoronaVac are the only vaccines for which such data has been published to date.

No studies reported effectiveness of any vaccine on reducing the risk of infection or disease among individuals exposed to P.1 or in settings of high P.1 transmission.

Added value of this study This study finds that vaccination with CoronaVac was 49.4% (95% CI 13.2 to 71.9) effective at preventing COVID-19 in a setting with likely high prevalence of the Gamma Variant of Concern. However, an analysis of effectiveness by dose was underpowered and failed to find significant effectiveness of the two-dose schedule of CoronaVac (estimated VE 37.1%, 95% CI -53.3 to 74.2).

Implications of all the available evidence These findings are suggestive for the effectiveness of CoronaVac in healthcare workers in the setting of widespread P.1 transmission but must be strengthened by observational studies in other settings and populations. Based on this evidence, there is a need to implement sustained non-pharmaceutical interventions even as vaccination campaigns continue.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

We are grateful for Pan American Health Organization's support to the Fundação de Vigilância em Saúde from Amazonas State and the Municipal Health Secretary of Manaus in making the databases available for analysis. JC and AS are supported by the Oswaldo Cruz Foundation (Edital Covid-19 - resposta rápida: 48111668950485). OTR is funded by a Sara Borrell fellowship (CD19/00110) from the Instituto de Salud Carlos III. OTR acknowledges support from the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa 2019-2023 Program and from the Generalitat de Catalunya through the CERCA Program.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Ethical Committee for Research of Federal University of Mato Grosso do Sul (CAAE: 43289221.5.0000.0021).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Deidentified databases as well as the R codes will be deposited in the repository https://github.com/juliocroda/VebraCOVID-19

https://github.com/juliocroda/VebraCOVID-19

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted June 24, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study
Matt D.T. Hitchings, Otavio T. Ranzani, Mario Sergio Scaramuzzini Torres, Silvano Barbosa de Oliveira, Maria Almiron, Rodrigo Said, Ryan Borg, Wade L. Schulz, Roberto Dias de Oliveira, Patricia Vieira da Silva, Daniel Barros de Castro, Vanderson de Souza Sampaio, Bernardino Cláudio de Albuquerque, Tatyana Costa Amorim Ramos, Shadia Hussami Hauache Fraxe, Cristiano Fernandes da Costa, Felipe Gomes Naveca, Andre M. Siqueira, Wildo Navegantes de Araújo, Jason R. Andrews, Derek A.T. Cummings, Albert I. Ko, Julio Croda
medRxiv 2021.04.07.21255081; doi: https://doi.org/10.1101/2021.04.07.21255081
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study
Matt D.T. Hitchings, Otavio T. Ranzani, Mario Sergio Scaramuzzini Torres, Silvano Barbosa de Oliveira, Maria Almiron, Rodrigo Said, Ryan Borg, Wade L. Schulz, Roberto Dias de Oliveira, Patricia Vieira da Silva, Daniel Barros de Castro, Vanderson de Souza Sampaio, Bernardino Cláudio de Albuquerque, Tatyana Costa Amorim Ramos, Shadia Hussami Hauache Fraxe, Cristiano Fernandes da Costa, Felipe Gomes Naveca, Andre M. Siqueira, Wildo Navegantes de Araújo, Jason R. Andrews, Derek A.T. Cummings, Albert I. Ko, Julio Croda
medRxiv 2021.04.07.21255081; doi: https://doi.org/10.1101/2021.04.07.21255081

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (162)
  • Allergy and Immunology (416)
  • Anesthesia (91)
  • Cardiovascular Medicine (863)
  • Dentistry and Oral Medicine (159)
  • Dermatology (98)
  • Emergency Medicine (251)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
  • Epidemiology (8571)
  • Forensic Medicine (4)
  • Gastroenterology (388)
  • Genetic and Genomic Medicine (1759)
  • Geriatric Medicine (167)
  • Health Economics (373)
  • Health Informatics (1249)
  • Health Policy (622)
  • Health Systems and Quality Improvement (468)
  • Hematology (196)
  • HIV/AIDS (378)
  • Infectious Diseases (except HIV/AIDS) (10318)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (213)
  • Neurology (1682)
  • Nursing (97)
  • Nutrition (252)
  • Obstetrics and Gynecology (328)
  • Occupational and Environmental Health (451)
  • Oncology (930)
  • Ophthalmology (264)
  • Orthopedics (102)
  • Otolaryngology (172)
  • Pain Medicine (114)
  • Palliative Medicine (40)
  • Pathology (253)
  • Pediatrics (538)
  • Pharmacology and Therapeutics (254)
  • Primary Care Research (209)
  • Psychiatry and Clinical Psychology (1775)
  • Public and Global Health (3853)
  • Radiology and Imaging (626)
  • Rehabilitation Medicine and Physical Therapy (320)
  • Respiratory Medicine (521)
  • Rheumatology (208)
  • Sexual and Reproductive Health (168)
  • Sports Medicine (158)
  • Surgery (191)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)